Time slot's time in Taipei (GMT+8)
2025/11/23 11:40-12:30 Room 201 ABC
- Lunch Symposium-衛采製藥股份有限公司 Eisai Taiwan Inc.
衛采製藥股份有限公司 Eisai Taiwan Inc.
- Time
- Topic
- Speaker
- Moderator
- 11:40-12:30
- Optimizing Motor Control and Beyond: Evidence of 3rd Generation MAOBi –Safinamide as Early Add-On Strategy
- Speaker:
Chun-Yu Chen
(Taiwan)
- Moderator:
Ming-Kuei Lu
(Taiwan)
- Chun-Yu Chen
- E-mail：justuscychen@nycu.edu.tw
Executive Summary：
Dr. Chun-Yu (Justus) Chen is a neurologist currently serving as a staff physician at the Neurological Institute of Taipei Veterans General Hospital and an assistant professor in the Department of Neurology at National Yang Ming Chiao Tung University. He earned both his MD and PhD from National Yang Ming Chiao Tung University, where his doctoral research explored the physiological interactions between sleep and the autonomic nervous system in both rodents and humans.
Dr. Chen completed his neurology residency at Taipei Veterans General Hospital and is board-certified in Neurology. He has advanced his expertise through specialized training in neuromodulation and electrophysiology for movement disorders at Toronto Western Hospital and the National Institute of Neurological Disorders and Stroke, NIH. His additional training includes sleep research at Beth Israel Deaconess Medical Center. Dr. Chen brings a strong combination of clinical experience and research in neurological disorders, offering comprehensive care and advancing neurological sciences.
Dr. Chun-Yu (Justus) Chen is a neurologist currently serving as a staff physician at the Neurological Institute of Taipei Veterans General Hospital and an assistant professor in the Department of Neurology at National Yang Ming Chiao Tung University. He earned both his MD and PhD from National Yang Ming Chiao Tung University, where his doctoral research explored the physiological interactions between sleep and the autonomic nervous system in both rodents and humans.
Dr. Chen completed his neurology residency at Taipei Veterans General Hospital and is board-certified in Neurology. He has advanced his expertise through specialized training in neuromodulation and electrophysiology for movement disorders at Toronto Western Hospital and the National Institute of Neurological Disorders and Stroke, NIH. His additional training includes sleep research at Beth Israel Deaconess Medical Center. Dr. Chen brings a strong combination of clinical experience and research in neurological disorders, offering comprehensive care and advancing neurological sciences.
Lecture Abstract：
Safinamide, a third-generation monoamine oxidase-B inhibitor (MAO-Bi), as an effective early add-on therapy in Parkinson's disease (PD) management. Safinamide offers a dual mechanism of action: it reversibly inhibits MAO-B to enhance dopaminergic transmission and modulates abnormal glutamate release by blocking voltage-dependent sodium and calcium channels. This multimodal activity helps optimize motor control by reducing OFF-time and improving motor symptoms without significantly increasing troublesome dyskinesias. Moreover, Safinamide shows benefits beyond motor symptoms, improving certain non-motor symptoms such as fatigue, mood, sleep quality, and pain, thereby enhancing overall quality of life in PD patients. Its reversible inhibition mechanism also minimizes risks of hypertensive crises and drug interactions, making it a safer option among MAO-B inhibitors. Recent clinical evidences support its use not only in advanced stages with motor fluctuations but also as an early adjunct to levodopa in early wearing-off patient, positioning Safinamide as a valuable therapeutic strategy for comprehensive Parkinson’s disease care.
Safinamide, a third-generation monoamine oxidase-B inhibitor (MAO-Bi), as an effective early add-on therapy in Parkinson's disease (PD) management. Safinamide offers a dual mechanism of action: it reversibly inhibits MAO-B to enhance dopaminergic transmission and modulates abnormal glutamate release by blocking voltage-dependent sodium and calcium channels. This multimodal activity helps optimize motor control by reducing OFF-time and improving motor symptoms without significantly increasing troublesome dyskinesias. Moreover, Safinamide shows benefits beyond motor symptoms, improving certain non-motor symptoms such as fatigue, mood, sleep quality, and pain, thereby enhancing overall quality of life in PD patients. Its reversible inhibition mechanism also minimizes risks of hypertensive crises and drug interactions, making it a safer option among MAO-B inhibitors. Recent clinical evidences support its use not only in advanced stages with motor fluctuations but also as an early adjunct to levodopa in early wearing-off patient, positioning Safinamide as a valuable therapeutic strategy for comprehensive Parkinson’s disease care.
